Two clinical case histories are presented that indicate that naive ingestion of the anorectic, phenylpropanolamine, may induce psychotic reactions in patients with preexisting diagnosed psychiatric disturbance. These clinical observations and concerns are buttressed by a review of the scientific literature relevant to the psychotic inducing effects of phenylpropanolamine and structurally similar sympathomimetic derivatives of β-phenylethylamine, such as amphetamine and ephedrine.
References
1.
Snyder, S.H. (1978). A “model schizophrenia” mediated by catecholamines. In: Amphetamine Use, Misuse, and Abuse. D.E. Smith (ed.). Boston: G.K. Hall, pp. 189–204.
2.
Bell, D.S. (1965). Comparison of amphetamine psychosis and schizophrenia.Br. J. Psychiatr.111: 701–707.
3.
Kalant, O.H. (1973). The Amphetamines: Toxicity and Addition, 2nd ed.Springfield, IL: Charles C Thomas.
4.
Kiloh, L.G., and Brandon, S. (1962). Habituation and addiction to amphetamines.Br. Med. J.2: 40–43.
5.
Weiner, N. (1980). Norepinephrine, epinephrine, and the sympathomirnetic amines. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 6th ed. A.G. Gilman, L.S. Goodman, and A. Gilman (eds.). New York: Macmillan, pp. 138–175.
6.
Dietz, A.J. (1981). Amphetamine-like reactions to phenylpropanolamine.JAMA245: 601–602.
7.
D'MELLO. A. (1969). Interaction between phenylpropanolamine and monamine oxidase inhibitors.J. Pharm. Pharmacol.21: 577–580.
8.
Raiteri, M., Bertollini, A., Angelini, F., and Levi, G. (1975). d-Amphetamine as a releaser or reuptake inhibitor of biogenic amines in synaptosomes.Eur. J. Pharmacol34: 189–195.
9.
Glowinski, J., and Axelrod, J. (1965). Effect of drugs on the uptake, release, and metabolism of H3-norepinephrine in the rat brain.J. Pharmacol. Exp. Ther.149: 43–49.
10.
Janowsky, D., EL-Yousef, M., Davis, J., and Sekerke, G. (1973). Provocation of schizophrenic symptoms by intravenous amphetamine administration. Arch. Gen. Psychiatr.28(2), 185–193.
11.
Angrist, B., Lee, H., and Gershon, S. (1974). The antagonism of amphetamine-induced symptomatology by a neuroleptic. Am. J. Psychiatr.131(7), 817–819.
12.
Zelger, J.L., and Carlini, E.A. (1981). Influence of cathinone (a-aminopropiophenone) and cathine (phenylpropanolamine) on circline behavior and on uptake and release of 3H dopamine in striatal slices in rats.Neuropharmacology20: 839–843.
13.
Ungerstedt, U. (1968). 6-Hydroxydopamine-induced degeneration of central monamine neurons.Eur. J. Pharmacol.5: 107–110.
14.
Schaffer, C.B., and Pauli, M.W. (1980). Psychotic reaction caused by proprietary oral diet agents.Am. J. Psychiatr.137: 1256–1257.
15.
Wharton, B.K. (1970). Nasal decongestants and paranoid psychosis.Br. J. Psychiatr.117: 439–440.
16.
Kane, F.J., and Green, B.Q. (1966). Psychotic episodes associated with the use of common proprietary decongestants.Am. J. Psychiatr.123: 484–487.
17.
Widerlov, E. (1979). Psykoser av fenylpropanolamin.Lakartidningen26: 4529–4530.
18.
Widerlov, E., Lonnerholm, G., and Norvenius, G. (1979). Phenylpropanolamine and mental disturbances.Lancet2: 1367–1368.
19.
Myrdal, U., and Hallberg, M. (1979). Varning for perorala nasdoppar (fenylpropanolamin).Lakartidningen76: 840–841.
20.
Rieger, G. (1981). Paranoid-halluzinatorische psychosen nach einnahme von d-nor-pseudoephedrin-haltigen appetitzuglern.Nervenarzt52: 423–425.
21.
Herridge, C.F., and A'Brook, M.F. (1968). Ephedrine psychosis.Br. Med. J.2: 160.
22.
Roxanas, M.G., and SPALDING. J. (1977). Ephedrine abuse psychosis.Med. J. Aust.2: 639–640.
23.
Segal, D., and JANOWSKY. D. (1978). Psychostimulant-induced behavioral effects: Possible models of schizophrenia. In: Psychopharmacology: A Generation of Progress. M. Lipton, A. DiMascio. and K. Killam (eds.). New York: Raven Press, pp. 1113–1123.
